Covered recipient · General Payments record
JAYNIER MOYA
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$1,741.44
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,741.44 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Chiesi USA, Inc. | $1,741.44 | 2 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAYNIER MOYA
NPI 1124288980 · CMS profile ID 278302
Allopathic & Osteopathic Physicians / Internal Medicine
PEMBROKE PINES, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $1,741.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Chiesi USA, Inc. | $870.72 | 01/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050859851 | CMS |
| Chiesi USA, Inc. | $870.72 | 01/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051592383 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2023, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,567,242.14 | 108 |
| PY2024 | Recipient | $1,161.49 | 6 |
| PY2024 | Principal investigator | $5,059,140.87 | 296 |
| PY2023 | Recipient | $2,506.25 | 1 |
| PY2023 | Principal investigator | $14,127,127.37 | 743 |
| PY2022 | Recipient | $24,618.00 | 1 |
| PY2022 | Principal investigator | $15,001,316.81 | 131 |
| PY2021 | Principal investigator | $6,255,399.36 | 48 |
| PY2020 | Principal investigator | $653,923.11 | 62 |
| PY2019 | Principal investigator | $748,551.83 | 218 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
108 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $22,607.00 | 12/22/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | No dispute reported | 06/30/2026 | 1226122204 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $11,687.00 | 12/11/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040161 |
| Principal investigator 1 | ModernaTX, Inc. | $86,483.28 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953677 |
| Principal investigator 1 | ModernaTX, Inc. | $45,919.86 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953681 |
| Principal investigator 1 | ModernaTX, Inc. | $7,886.15 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953685 |
| Principal investigator 1 | ModernaTX, Inc. | $1,468.58 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953689 |
| Principal investigator 1 | ModernaTX, Inc. | $3,281.85 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953693 |
| Principal investigator 1 | ModernaTX, Inc. | $9,081.88 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953695 |
| Principal investigator 1 | ModernaTX, Inc. | $3,407.14 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953697 |
| Principal investigator 1 | ModernaTX, Inc. | $20,266.92 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953703 |
| Principal investigator 1 | ModernaTX, Inc. | $8,951.25 | 11/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953705 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,841.00 | 11/13/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040159 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,053.00 | 10/27/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | No dispute reported | 06/30/2026 | 1226122148 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,906.40 | 10/20/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226122141 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,678.50 | 10/14/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040157 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,156.80 | 10/06/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226122128 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,943.50 | 09/17/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040155 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,906.40 | 09/15/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226122092 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $31,159.00 | 09/15/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226122099 |
| Principal investigator 1 | ModernaTX, Inc. | $4,800.00 | 09/03/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953691 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,701.37 | 08/25/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226122096 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,841.00 | 08/19/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040153 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,994.40 | 08/18/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226122063 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $640.00 | 08/11/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226122067 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,580.40 | 08/11/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226122075 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 08/08/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,831.00 | 08/08/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198938 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,950.00 | 08/06/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040151 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,168.00 | 08/04/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | No dispute reported | 06/30/2026 | 1226122050 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $63,700.00 | 07/28/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226122040 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,189.50 | 07/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040147 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,950.00 | 07/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040149 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,927.00 | 07/21/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | No dispute reported | 06/30/2026 | 1226122030 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,088.00 | 07/14/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226121968 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $38,280.80 | 07/14/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226122014 |
| Principal investigator 1 | Chiesi USA, Inc. | $1,000.00 | 07/09/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234404049 |
| Principal investigator 1 | Chiesi USA, Inc. | $500.00 | 07/09/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234404053 |
| Principal investigator 1 | Chiesi USA, Inc. | $5,000.00 | 07/09/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234404058 |
| Principal investigator 1 | Chiesi USA, Inc. | $1,000.00 | 07/09/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234404063 |
| Principal investigator 1 | Chiesi USA, Inc. | $1,000.00 | 07/09/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234404067 |
| Principal investigator 1 | Chiesi USA, Inc. | $1,000.00 | 07/09/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234404071 |
| Principal investigator 1 | Chiesi USA, Inc. | $500.00 | 07/09/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | No dispute reported | 06/30/2026 | 1234404074 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $50.00 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121948 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $200.00 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121952 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,600.00 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121961 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,800.00 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121964 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,360.00 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121972 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,585.00 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121976 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $714.44 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121980 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,420.00 | 07/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121985 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,688.40 | 07/02/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226121956 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,942.50 | 06/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040145 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,850.00 | 06/23/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121940 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,270.00 | 06/23/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121944 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,844.00 | 06/20/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198812 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,249.00 | 06/16/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198807 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $63,105.80 | 06/11/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT | No dispute reported | 06/30/2026 | 1192170921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,171.00 | 06/10/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198892 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $42,700.60 | 06/09/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226121929 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,136.00 | 06/04/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198842 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $33,329.49 | 05/28/2025 | Non-covered Recipient Entity Elias Research Associates Llc | An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia | No dispute reported | 06/30/2026 | 1235997553 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,097.50 | 05/22/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040143 |
| Principal investigator 1 | Janssen Research & Development, LLC | $149,585.00 | 05/20/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198865 |
| Principal investigator 1 | Janssen Research & Development, LLC | $245,520.00 | 05/13/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198922 |
| Principal investigator 1 | Janssen Research & Development, LLC | $846,950.00 | 05/12/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198949 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $25,036.00 | 05/12/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226121926 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,452.00 | 05/05/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121916 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,160.00 | 05/05/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 | No dispute reported | 06/30/2026 | 1226121919 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $29,606.00 | 05/05/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | No dispute reported | 06/30/2026 | 1226121922 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,800.00 | 04/30/2025 | Non-covered Recipient Entity AVICENNA DM CLINICAL RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185545947 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $35,902.80 | 04/28/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226121912 |
| Principal investigator 1 | Janssen Research & Development, LLC | $69,300.00 | 04/24/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198957 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $23,744.50 | 04/24/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,272.00 | 04/22/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198818 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,440.00 | 04/22/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,350.00 | 04/22/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $245,155.00 | 04/22/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198883 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,680.00 | 04/22/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198908 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,403.00 | 04/16/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198878 |
| Principal investigator 1 | ModernaTX, Inc. | $1,980.00 | 04/16/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953675 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,280.00 | 04/15/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $420.00 | 04/10/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198849 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37,492.70 | 04/07/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226121903 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $45,278.40 | 04/02/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226121884 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $70,081.30 | 04/02/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226121888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,665.00 | 03/24/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198900 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $58,771.00 | 03/24/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | No dispute reported | 06/30/2026 | 1226121890 |
| Principal investigator 1 | ModernaTX, Inc. | $7,800.00 | 03/21/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953673 |
| Principal investigator 1 | ModernaTX, Inc. | $8,850.00 | 03/21/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953679 |
| Principal investigator 1 | ModernaTX, Inc. | $9,600.00 | 03/21/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953687 |
| Principal investigator 1 | ModernaTX, Inc. | $2,550.00 | 03/21/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953699 |
| Principal investigator 1 | ModernaTX, Inc. | $1,400.00 | 03/20/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953701 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,198.00 | 03/20/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040139 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $30,603.90 | 03/17/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226121900 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,500.00 | 03/14/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT | No dispute reported | 06/30/2026 | 1192170917 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $36,848.00 | 03/14/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT | No dispute reported | 06/30/2026 | 1192170925 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,484.00 | 03/04/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226121872 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $33,689.50 | 02/27/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040165 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $196,104.50 | 02/26/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER, LLC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185545945 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/21/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040297 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,300.00 | 02/19/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198916 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $67,790.60 | 02/18/2025 | Non-covered Recipient Entity Pines Care Research Center Llc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226121898 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $20,065.50 | 01/30/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244040163 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,650.00 | 01/22/2025 | Non-covered Recipient Entity VIDA MEDICAL CENTERS PEMBROKE PINE | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) | No dispute reported | 06/30/2026 | 1190313087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,150.00 | 01/21/2025 | Non-covered Recipient Entity Pines Care Rsrch Ctr | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175198826 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $168,172.21 | 01/17/2025 | Non-covered Recipient Entity Pines Care Research Center, Llc | An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | No dispute reported | 06/30/2026 | 1235994595 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $65,515.92 | 01/06/2025 | Non-covered Recipient Entity Pines Care Research Center, Llc | A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) | No dispute reported | 06/30/2026 | 1235994593 |
| Principal investigator 1 | ModernaTX, Inc. | $9,000.00 | 01/06/2025 | Non-covered Recipient Entity PINES CARE RESEARCH CENTER LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252953683 |